Alamar Biosciences plans to sell ~9.375 million shares at $15‑$17 each, potentially raising just over $159 million.
Investor demand exceeds 10 times the supply, driven by long‑only and health‑care focused investors.
The IPO is expected to price at the top of the $15‑$17 range or higher, per Bloomberg.
Shares will debut on Nasdaq Global Select Market Friday under ticker ALMR, with JPMorgan, BofA, TD, Leerink and Stifel as underwriters.